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ABSTRACT 50 
Rationale 51 
Tuberculosis treatment lasts for six months or more. Treatment adherence is critical; 52 
regimen length, among other factors, makes this challenging. Globally, analyses mapping 53 
common types of non-adherence are lacking. For example, is there a greater challenge from 54 
early treatment cessation (discontinuation) or intermittent missed doses (suboptimal dosing 55 
implementation)? This is essential knowledge for the development of effective interventions, 56 
more ‘forgiving’ regimens, and to direct National Tuberculosis Programs. 57 
 58 
Objective 59 
Granularly describe how patients take their tuberculosis medication and the temporal factors 60 
associated with missed doses. 61 
 62 
Methods 63 
Pulmonary tuberculosis patients enrolled in the control arm of a pragmatic cluster-64 
randomized trial in China of electronic reminders to improve treatment adherence were 65 
included. Treatment was the standard six-month course (180 days), dosed every other day 66 
(90 doses). Medication monitor boxes recorded adherence (box opening) without prompting 67 
reminders. 68 
  69 
Patterns of adherence were visualized and described. Mixed-effects logistic regression 70 
models examined the temporal factors associated with per-dose suboptimal dosing 71 
implementation, adjusting for clustering by participant. Cox regression models examined the 72 
association between early suboptimal dosing implementation and permanent 73 
discontinuation. 74 
 75 
Results 76 
Across 780 patients, 16,794 of 70,200 doses were missed (23.9%), 9,487 from suboptimal 77 
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dosing implementation (56.5%). By 60 days, 5.1% of participants had discontinued, 14.4% 78 
by 120 days. Most participants (95.9%) missed at least one dose. The majority of gaps were 79 
of a single dose (71.4%), although 22.6% of participants had at least one gap of two weeks’ 80 
or more. 81 
 82 
In adjusted models, the initiation-continuation phase transition (odds ratio 3.07 [95% 83 
confidence interval 2.68-3.51]) and national holidays (1.52 [1.39-1.65]) were associated with 84 
increasing odds of suboptimal dosing implementation. Early-stage suboptimal dosing 85 
implementation was associated with increased discontinuation rates.   86 
 87 
Conclusions 88 
Digital tools provide an unprecedented step-change in describing and addressing non-89 
adherence. In our setting, non-adherence was common; patients displayed a complex range 90 
of patterns. Dividing non-adherence into suboptimal dosing implementation and 91 
discontinuation, both were found to increase over time. Discontinuation was associated with 92 
early suboptimal dosing implementation. These apparent causal associations between 93 
temporal factors and non-adherence present opportunities for targeted interventions. 94 
 95 
Clinical trial registration 96 
ISRCTN46846388 97 
 98 
Primary source of funding 99 
Bill & Melinda Gates Foundation (51914) 100 
  101 
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INTRODUCTION 102 
In 2017, 6.4 million incident tuberculosis (TB) cases were reported globally and an estimated 103 
3.6 million went undiagnosed or were not notified.(1) Finding and treating these missing 104 
patients is a key target of the World Health Organization (WHO); this requires substantial 105 
international investment. It is critically important to protect this investment by providing 106 
effective treatment to every diagnosed patient. 107 
 108 
The standard treatment for drug sensitive TB lasts for six months. Numerous studies have 109 
documented that patients struggle to adhere to the full course of therapy. An estimated 4-110 
35% demonstrate poor adherence.(2-11) Although various definitions have been used, poor 111 
adherence is associated with a reduced likelihood of sputum conversion,(3) greater risk of 112 
an unsuccessful treatment outcome,(4, 8, 12-15) and the development of drug 113 
resistance.(16-19) Non-adherence to TB treatment is associated with various factors; those 114 
that are patient-related, derived from the healthcare provider-patient relationship, the 115 
regimen itself, and the healthcare system.(20) 116 
 117 
In trials and observational studies, overly simplistic and non-evidence-based 80-90% 118 
adherence thresholds have traditionally been used to signify adequate adherence.(12, 21-119 
23) Recently, however, the importance of highly accurate means of measuring adherence 120 
within clinical trials has been acknowledged by WHO as a key part of trial design.(24) 121 
Realistically, two core domains need to be considered when mapping adherence- 122 
persistence (time between first and last doses; capturing initiation and discontinuation) and 123 
dosing implementation (taking doses not as recommended e.g. skipping weekends).(25) 124 
These components constitute ‘therapeutic coverage’, the proportion of time patients are 125 
exposed to efficacious drug concentrations.(26) Detailed mapping of adherence patterns has 126 
been missing from the TB literature to date. 127 
 128 
Knowledge of how exactly TB patients take their medications and predictors of when non-129 
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adherence is most likely to occur is critical for the directed design of interventions to improve 130 
adherence, the development of regimens that are more ‘forgiving’ of non-adherence, and to 131 
help clinicians know when to intervene with non-adherent patients. Currently, the relative 132 
burden of suboptimal dosing implementation and discontinuation is unknown globally; 133 
interventions to address these two components of non-adherence may look quite different. 134 
This is a critical knowledge gap when it comes to reducing the burden of non-adherence, 135 
which is impeding the most cost-effective implementation of the WHO guidelines on digital 136 
adherence technologies for TB treatment.(27) 137 
 138 
Utilizing data collected from a trial of electronic reminders to improve medication adherence 139 
in China, we aimed to granularly describe how TB patients take their treatment and if 140 
temporal factors were causally associated with missed doses in order to inform control 141 
efforts. Components of this study have been previously reported through a conference 142 
abstract.(28) 143 
 144 
 145 
METHODS 146 
Parent study and study population for analysis 147 
The parent study- a pragmatic cluster randomized trial of electronic reminders to improve 148 
treatment adherence among pulmonary TB patients in People’s Republic of China- from 149 
which these data has been derived has been described before (Online supplement 150 
Additional Methods).(29) Participants were enrolled into the study between 1st June 2011 151 
and 7th March 2012. Only participants in the control arm of the trial were included in this 152 
cohort study in order to capture usual patterns of treatment adherence in the absence of an 153 
intervention (Online supplement Additional Methods). 154 
 155 
Measuring and defining adherence to treatment 156 
Adherence to each dose of treatment was documented by a medication monitor box (Online 157 
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supplement Additional Methods). The box captured every date and time on which it was 158 
opened; box opening did not necessarily mean that drugs were taken. Medication was dosed 159 
every other day (as per the National TB Program [NTP] standard at the time), for 90 doses 160 
over a 180-day period. If the box was opened at least once within each two-day dosing 161 
window this was recorded as adherence. The standard six-month regimen for drug sensitive 162 
TB was used (two months of isoniazid, rifampicin, ethambutol, pyrazinamide, followed by 163 
four months of isoniazid and rifampicin). Medication was not dosed in combination pills. 164 
 165 
Non-adherence data from the monitor was coded, and categorized as a dose missed due to 166 
suboptimal dosing implementation versus a dose missed due to permanent discontinuation, 167 
using accepted terminology as per Vrijens et al.(25) Discontinuation was defined as ceasing 168 
to adhere to treatment and not re-commencing both a) at any point during the 180-day 169 
period and b) after this period but before the end of the trial. Discontinuation is different from 170 
the programmatically defined term ‘lost to follow-up’ (previously known as ‘default’), when 171 
either a patient’s treatment is interrupted for consecutive two months or more, or a patient 172 
does not start treatment. Suboptimal dosing implementation refers to all doses missed 173 
during the 180-day period, aside from those due to discontinuation. The term ‘suboptimal’ is 174 
not intended to imply a judgement as to the appropriate level of adherence/type of 175 
adherence pattern required to achieve a positive treatment outcome, but rather reflects an 176 
implementation level below 100% of doses taken. 177 
 178 
Temporal exposures and potential confounders 179 
The following temporal measures were calculated from the medication monitor data: 1) day 180 
of the week, 2) treatment month, 3) whether the dose fell on a Chinese national holiday, 4) 181 
whether the patient was in the initiation or continuation phase of treatment (see Online 182 
supplement Additional Methods). 183 
 184 
Additionally, data were available for a series of potential confounders, all of which were self-185 
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reported at entry into the study. These included age, sex, marital status, educational level, 186 
occupation, household income, type of medical insurance, registration status, and distance 187 
from home to TB clinic. The county/district in which the participant lived was grouped into 188 
whether it was broadly rural or urban. 189 
 190 
Statistical methods 191 
Descriptive analyses 192 
Analyses were undertaken in Stata 15 and graphs plotted in Microsoft Excel. 193 
 194 
Adherence to treatment was described using the following summary measures: the overall 195 
percentage of doses taken, average duration that a patient was on treatment before ceasing 196 
completely, percentage of participants achieving an 80% adherence threshold, and 197 
percentage achieving a 90% threshold. In order to account for clustering, for each measure 198 
the mean was calculated per county/district and then the geometric mean taken across the 199 
county/district values. 200 
 201 
Adherence over time, grouped by different percentage intervals, was graphically visualized 202 
using lasagna plots, in which white indicates non-adherence.(30)  203 
 204 
Line graphs were used to visualize non-adherence due to suboptimal dosing implementation 205 
versus permanent discontinuation from treatment for all participants in the study and by 206 
adherence levels in the initiation phase.(31) After plotting these graphs, we decided to 207 
separate suboptimal dosing implementation and discontinuation in the remaining analyses. 208 
 209 
The length and number of gaps in treatment due to suboptimal dosing implementation were 210 
described using scatter plots. 211 
 212 
 213 
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Associations between temporal factors and suboptimal dosing implementation 214 
We used mixed-effects logistic regression to examine the factors associated with non-215 
adherence due to suboptimal dosing implementation, treating each dose as an observation 216 
and adjusting for clustering by individual. We focused on temporal factors, including 217 
weekends, national holidays, and the initiation-continuation phase transition (Model 1) or 218 
treatment months (Model 2). Our methodology- including details of model selection through 219 
the use of directed acyclical graphs, determination of a priori confounders, and assessment 220 
of potential effect modification- is detailed elsewhere (Online supplement Additional 221 
Methods). The impact of using different confounder sets on our findings was explored 222 
through Models 1A-F (Online supplement Additional Methods). Both approaches sought to 223 
address all confounding using different confounder sets to support the drawing of causal 224 
conclusions from observational data.(32) 225 
 226 
The potential presence of an interaction between the three temporal factors weekends, 227 
national holidays, and the initiation-continuation phase transition and a) county/district or b) 228 
distance from home to TB clinic were also explored using likelihood ratio tests (LRTs) 229 
(Models 1G-H). 230 
 231 
Associations between early suboptimal dosing implementation and time to 232 
discontinuation 233 
Cox proportional hazards regression was used to assess whether early suboptimal dosing 234 
implementation, either in the initiation phase (Model 3) or month 1 (Model 4), was associated 235 
with time to discontinuation. Individuals who had discontinued in the initiation phase and 236 
month 1 were excluded, respectively, in order to preserve the temporality of the association. 237 
Further details on adjustment for confounding, etc., are presented in Online supplement 238 
Additional Methods. We report sensitivity analyses on the impact of confounding by 239 
county/district (Models 3F, 4F) and excluding individuals who discontinued during the last 240 
three doses of treatment (Models 3G, 4G). The potential presence of an interaction between 241 
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early suboptimal dosing and a) county/district or b) distance from home to the TB clinic were 242 
also explored using LRTs. 243 
 244 
Ethical approval 245 
The trial was approved by the ethics committees of the Chinese Center for Disease Control 246 
and Prevention (201008) and the London School of Hygiene & Tropical Medicine (5704). All 247 
participants provided written consent prior to inclusion in the trial. 248 
 249 
 250 
RESULTS 251 
Characteristics of the study population 252 
Of the 1,104 individuals randomized to the control arm of the trial, 209 (18.9%) had technical 253 
issues with the medication monitor due to power outage problems, as indicated by the box 254 
resetting the date to a baseline value (Online supplement Figure E1). A further 10.4% of 255 
patients (115) were excluded, as events such as hospitalization for more than three days 256 
removed the potential for treatment to be monitored for the entire period. Thus 780 (70.7%) 257 
patient’s data were available for analysis. A comparison of the included and excluded 258 
patients revealed similarity in terms of baseline characteristics, except for county/district and 259 
distance from home to the TB clinic (Table E1). 260 
 261 
The baseline characteristics of participants are presented in Table 1. Individuals were 262 
generally male (535, 68.6%). More than half were under the age of 50 (525, 67.3%). 263 
Farming was the largest occupation (384, 49.2%), with 516 (66.2%) individuals living in 264 
counties/districts deemed rural and 500 (64.1%) insured through rural co-operatives. 265 
 266 
Summary measures of overall adherence 267 
Across all 780 study participants, 70,200 doses were scheduled during the 180-day period; 268 
16,794 of these were missed (23.9%). The geometric mean number of doses taken was 269 
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68/90 (75.6%). The geometric mean duration on treatment was 80 doses (i.e. 160 days) 270 
before discontinuation.  271 
 272 
Overall adherence over time 273 
Lasagna plots of adherence over time demonstrated the distribution of participants in 20% 274 
adherence intervals, with 473/780 (60.6%) in the highest category of ≥80-100% adherent 275 
(Figure 1). A clear ‘staggered’ pattern was observed in the lowest categories that 276 
corresponded to drop-offs in adherence with each passing month (15 doses, 30 days). 277 
Although there was a reduction in adherence over time, erratic non-adherence (suboptimal 278 
dosing implementation) was observed throughout the treatment period. 279 
 280 
The relative importance of non-adherence due to the permanent discontinuation of treatment 281 
versus suboptimal dosing implementation is shown in Figure 2a. Of the 16,794 missed 282 
doses, 9,487 were due to suboptimal dosing implementation (56.5%) and the remainder 283 
discontinuation. The impact of discontinuation was demonstrably stronger over time. By the 284 
end of month 2 5.1% of individuals had discontinued treatment; this figure was 14.4% by the 285 
end of month 4 and continued to increase during the last two months, until it reached 36.3% 286 
at the end of the 180-day period. The latter figure reflects the fact that discontinuation 287 
captures treatment cessation without recommencement at any time point, including 288 
cessation at the last (90th) dose. 289 
 290 
When the 121 participants with <80% adherence in the initiation phase were examined 291 
separately, they demonstrated sharp and sustained reductions in adherence due to both 292 
discontinuation and suboptimal dosing implementation (Figure 2c). 293 
 294 
Gaps in adherence (suboptimal dosing implementation) 295 
Suboptimal dosing implementation was demonstrated by 748/780 (95.9%) participants i.e. 296 
they displayed at least one gap in their treatment of one dose or more that was not due to 297 
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discontinuation. Overall, a total of 4,677 gaps were recorded, of which 71.4% (3,337/4,677) 298 
were for one dose only. The population median of the median gap length per participant was 299 
one and the interquartile range (IQR) 1-1 (Figure 3a). When the maximum gap length per 300 
participant was examined, the median across the population was two doses (IQR 1-6; Figure 301 
3b). Of the 780 individuals, 368 (47.2%) had at least one gap of three doses (roughly a 302 
week) or more and 176 (22.6%) of seven doses (a fortnight) or more. 303 
 304 
Associations between suboptimal dosing implementation and temporal factors 305 
Our analysis of suboptimal dosing implementation and temporal factors was composed of 306 
780 patients and 62,893 dose observations (Table 1). In unadjusted analyses, a strong 307 
association was seen between the initiation-continuation phase transition and suboptimal 308 
dosing implementation. The continuation phase was associated with triple the odds of 309 
suboptimal dosing implementation (odds ratios [OR] 3.09 [95% confidence interval {CI} 2.70-310 
3.54]). This mirrors the month-by-month findings, where suboptimal dosing implementation 311 
increased from 6.8% of doses in treatment month 1 to 19.7% in month 6. Sunday was 312 
associated with greater suboptimal dosing implementation than the other days of the week 313 
(p<0.001). Compared to weekdays, weekends were associated with a small increase in the 314 
odds of suboptimal dosing implementation (1.13 [1.07-1.19]). National holidays were 315 
associated with a larger increase in odds (1.62 [1.49-1.75]; 14.6% to 20.5%). 316 
 317 
In an adjusted model controlling for age as a linear variable, sex and urban/rural setting, and 318 
with a random effect on the initiation-continuation variable ([LRT p-value <0.001), all three 319 
temporal variables were associated with greater odds of suboptimal dosing implementation 320 
(weekends: 1.14 [1.08-1.20]), national holiday: 1.52 [1.39-1.65]), initiation-continuation 321 
transition 3.07 [2.68-3.51] (Model 1). There was no evidence for interactions between the 322 
initiation-continuation transition and national holidays (LRT p-value 0.97) or weekends (LRT 323 
p-value 0.07). These findings were robust to adjustment for different combinations of 324 
confounders (Table E2; Models 1A-F). 325 
13 
 
 326 
Tests for interaction were performed between the three temporal factors and county/district 327 
or distance. For distance, the LRT p-values for the initiation-continuation phase transition, 328 
holidays and weekends were 0.52, 0.97 and 0.91, respectively. For county/district, the LRT 329 
p-values for the initiation-continuation phase transition, holidays and weekends were 0.01, 330 
<0.001, 0.79, respectively. We thus undertook stratified analyses by county/district of the 331 
relationship between suboptimal implementation and a) the initiation-continuation phase 332 
transition (Table E3, Model 1G) or b) holidays (Table E4, Model 1H). Although the 333 
magnitude of the relationship between these two temporal factors and suboptimal 334 
implementation altered by county, the direction of effect was the same in all instances, 335 
barring one instance where the CI crossed the null (Baiquan, Model 1H; 0.94 [0.75-1.18]). 336 
 337 
Given the striking initiation-continuation phase effect found in these models, but also the 338 
more gradual pattern of reducing adherence demonstrated in Figure 1, the association 339 
between treatment month and suboptimal dosing implementation was assessed. A random 340 
effect was included on the treatment month (LRT p-value <0.001), which was treated as a 341 
categorical variable. An interaction was documented between treatment month and national 342 
holidays (LRT p-value 0.01), but the statistical evidence was less certain for an interaction 343 
between treatment month and weekends (LRT p-value 0.06). 344 
 345 
Within a model containing the treatment month-national holiday interaction (Model 2), the 346 
association between weekends and the odds of non-adherence due to suboptimal dosing 347 
implementation changed little from Model 1 (1.14 [1.08-1.20]). From month-to-month, the 348 
likelihood of suboptimal dosing implementation approximately increased and was particularly 349 
pronounced for doses that fell on national holidays (Table 2). A dose falling on a national 350 
holiday was positively associated with suboptimal dosing implementation, with the largest 351 
increase in odds in the last month of treatment, but no clear trend month-to-month (Table 2).  352 
 353 
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Associations between time to discontinuation and early suboptimal dosing 354 
implementation 355 
Among the individuals included in the study, 109 were found to stop treatment without 356 
recommencing within the 90-dose period, but to later recommence before the end of the trial. 357 
The latest dose taken was at 254 days. These individuals were not classified as 358 
discontinuing. Patients who discontinued during the relevant implementation period were 359 
excluded in order to preserve temporality within any associations. Thus, 740 patients 360 
contributed to an analysis of discontinuation and suboptimal dosing implementation in the 361 
initiation phase and 775 when suboptimal dosing implementation in month 1 was instead 362 
considered (Table 1). 363 
 364 
In unadjusted analyses, increased suboptimal dosing implementation in the initiation phase 365 
and month 1 were associated within an increase in the likelihood of discontinuation (Table 366 
1). These findings were robust in an adjusted analysis (Table 3). The impact of ≥80 to <90% 367 
versus ≥90% adherence was less certain for the initiation phase analysis (Model 3), but 368 
more suggestive of a dose-response association in the month 1 analysis (Model 4). 369 
Considering different confounder sets, these models were robust to adjustment for a fixed 370 
effect for county/district rather than urban/rural (Table E5; Models 3F and 4F). When the 52 371 
individuals who discontinued from dose 87 onwards were excluded, our effect estimates 372 
increased for both the initiation phase and month 1 analyses (Table E5; Models 3G and 4G). 373 
Tests for interaction between early suboptimal dosing implementation and county/district 374 
revealed no evidence for an effect (LRT p-value 0.19). 375 
 376 
DISCUSSION 377 
Our analysis of adherence- both suboptimal dosing implementation and discontinuation- 378 
among pulmonary TB patients in China provides the first detailed description of how doses 379 
are missed over the six-month treatment period. We found that participants took 76% of their 380 
doses; 61% took 80% or more. The use of simple percentage thresholds, however, masks 381 
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important variation in the patterns of missed doses over time.  382 
 383 
Of all missed doses, 43% were due to discontinuation. A steady increase in non-adherence 384 
due to both suboptimal dosing implementation and discontinuation over time was observed. 385 
At two months, 5.1% of participants had discontinued their medication, 14.4% at four 386 
months, and 36.3% by the end of the 180-day period. During the intensive phase of 387 
treatment (the first two months), suboptimal dosing implementation accounted for the 388 
majority of non-adherence. Of the 19% of patients who were non-adherent at the end of the 389 
intensive phase, discontinuation accounted for 27% of the non-adherence and suboptimal 390 
dosing implementation the remainder. During the continuation phase (months 3 to 6), the 391 
odds of suboptimal dosing implementation were three times higher than during the intensive 392 
phase, but the percentage of patients with suboptimal dosing implementation remained 393 
stable at 17-20%. However, the percentage of those who discontinued treatment continued 394 
to accumulate, and by the fifth month, discontinuation accounted for 52% of all non-395 
adherence. 396 
 397 
We identified an important association between suboptimal dosing implementation early in 398 
the course of treatment and subsequent discontinuation. Suboptimal dosing implementation 399 
in the first month or overall initiation phase (months 1 and 2) was associated with higher 400 
discontinuation rates. Across participants, 96% demonstrated suboptimal dosing 401 
implementation; around three quarters of gaps were for one dose only. Nevertheless, 47% of 402 
individuals had potentially clinically important gaps of three consecutive doses or more and 403 
23% of seven consecutive doses (a fortnight) or more. The odds of suboptimal dosing 404 
implementation were higher on national holidays (OR 1.52). 405 
 406 
The findings of this study provide several insights into how drug-sensitive TB treatment can 407 
be improved. Firstly, NTPs should take seriously the problem of non-adherence to treatment, 408 
which is under-recognized. In this study, a high percentage of patients had gaps of a week 409 
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or more in their treatment due to suboptimal dosing implementation. If these gaps are not 410 
recognized and treatment is not adjusted accordingly, then long-term, relapse-free, cure of 411 
these patients may be compromised. NTPs should place a much higher priority on improving 412 
adherence during treatment and not simply focus on ensuring completion. 413 
 414 
Second, this study identified the importance of early adherence. Adherence worsened over 415 
the course of treatment, especially after the shift into the continuation phase. We also found 416 
an association between discontinuation and early suboptimal dosing implementation. Thus 417 
improving adherence early in the course of treatment may be important to prevent later non-418 
adherence. 419 
 420 
Third, this study highlights the importance of granular adherence data on individual patients. 421 
Early identification of individuals with poor adherence or who discontinue would improve the 422 
likelihood of success of adherence-promoting interventions. Identification of such individuals 423 
could result in the initiation of differentiated care, which would include more tailored 424 
adherence support for these patients. The design of such behavioral interventions should 425 
take into account data on the types of non-adherence displayed by the target population and 426 
their causes. For example, plans to support medication adherence may need to be 427 
proactively generated with patients before holiday periods, where travel to different locations 428 
may generate greater concern about stigma and result in missed doses. Adherence should 429 
also be monitored after such interventions are deployed, to check for improvement. Digital 430 
technologies to record adherence- e.g. by using pill bottle opening as a surrogate for 431 
medication intake- have been available for many years and are starting to be rolled out 432 
globally, despite operational barriers such as cost.(33) Such technologies, however, provide 433 
an opportunity to monitor TB treatment adherence for individual patients on a large 434 
scale.(33)  435 
 436 
Fourth, these results lend support to the development of shorter treatment regimens, which 437 
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may avoid the adherence drop-off later in treatment that is currently observed. Such 438 
regimens have not yet demonstrated non-inferiority (34-36) and will likely, however, increase 439 
the importance of each individual dose in ensuring cure. Retrieving patients who default from 440 
treatment is a large financial burden on NTPs; this could also be reduced with shorter 441 
regimens that result in less discontinuation. We also highlight the value of examining  442 
discontinuation of treatment, rather than programmatically defined loss to follow-up/default, 443 
in terms of capturing effective drug exposure.  444 
 445 
Overall, studies prior to ours have provided the initial basis of a link between different 446 
adherence patterns and treatment outcomes in drug sensitive disease.(2-9, 11) For 447 
example, missing 8-16% of doses has been associated with 25 times the odds of remaining 448 
sputum positive,(3) adhering below a 90% threshold with 5.9 times the rate of an 449 
unfavorable outcome,(15) adhering below a 75% threshold with 3.2 times the odds of 450 
recurrence,(14) adhering below a 90% threshold with 3.4 times the odds of mortality,(4) and 451 
‘irregular’ drug taking such that treatment had to be extended 2.5 times increased odds of 452 
relapse.(8) Conversely, a regimen simulating <67% adherence had no impact on 453 
recurrence.(37) Additionally, previous studies have documented a 17% additional hazard per 454 
month of acquired drug resistance if adherence is <80%,(19) or 19.7 times the odds of with 455 
half month gaps, non-engagement or <80% adherence.(16) This association is not simple; 456 
particularly poor adherence may exert little selective pressure.(17) In drug resistant disease, 457 
there is a smaller but less contradictory evidence base in terms of the implications of non-458 
adherence: long interruptions and <80-90% adherence have been associated with poorer 459 
outcomes.(17, 19, 38, 39) What these studies lack- which potentially explains their 460 
conflicting findings- is a granular exploration of how non-adherence influences treatment 461 
outcomes using reliable sources of adherence data.(23) Our study indicates that poor 462 
adherence is complicated and heterogeneous; future studies will require granular dose-by-463 
dose data in order to properly assess the non-adherence-outcomes relationship. Future 464 
studies should collect detailed adherence data- moving away from monthly self-reported 465 
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information and chart reviews- to ascertain how they correlate to therapeutic coverage, 466 
pharmacokinetics (TB drugs with a short half-life are predicted to be less forgiving), sputum 467 
conversion rates, treatment outcomes,(40) relapse (the gold standard outcome measure), 468 
and the development of drug resistance. 469 
 470 
This is the most detailed analysis to date of treatment adherence in TB, which makes use of 471 
exceptionally granular adherence data. It does, however, have its limitations. Whether drug 472 
intake was supported (e.g. observed by a family member) or self-administered was not 473 
documented, potentially leaving residual confounding. Opening the medication monitor box 474 
does not necessarily mean that drugs were taken, although a validation study has indicated 475 
high correlation with urine rifampicin levels.(41) Given that each dose could have been taken 476 
during a two-day period, non-differential misclassification of the temporal exposure variables 477 
may have occurred, biasing effect estimates towards the null. As fixed dose combination pills 478 
were not used, it is possible that non-adherence was underestimated per drug, as individuals 479 
may have chosen not to take all their pills per dose. The exclusion of participants for whom a 480 
whole dosing history was not available may have resulted in selection bias, as excluded 481 
participants differed from included participants in terms of the county/district in which they 482 
lived and their distance from home to their local TB clinic. On the basis of tests for 483 
interaction, it seems unlikely, however, than temporal factors (the focus of our analysis) are 484 
systematically differently associated with adherence across different levels of these 485 
variables. Data were missing on participant’s personal holidays, which could be biasing the 486 
effect size towards the null. Furthermore, part of the national holiday effect could represent 487 
individuals not transporting their monitor boxes with them when they travel, but nevertheless 488 
taking their medication. Socio-behavioral data on factors associated with non-adherence, 489 
such as stigma, were not collected, potentially resulting in residual confounding. Finally, 490 
participants may have been aware that they would be less likely to have taken their drugs at 491 
weekends and thus switched their doses from weekends to weekdays to avoid non-492 
adherence. This is a function of the every-other-day dosing of the regimen and would result 493 
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an over-emphasized effect size. 494 
 495 
Four key factors in our study affect generalizability: this was a 1) single country dataset of 2) 496 
pulmonary TB patients 3) enrolled in a trial who 4) took their drugs every other day. Being 497 
enrolled in a trial is thought to boost adherence and the individuals who consent to 498 
participate are often more likely to be adherent; adherence data are therefore also needed 499 
from observational studies globally.(42-44) We thus recommend the need for future studies 500 
using granular adherence data from observational studies undertaken in other nations. 501 
 502 
CONCLUSIONS 503 
In conclusion, we demonstrate how non-adherence to TB treatment is a complex issue that 504 
needs to be taken seriously. Adherence worsens over the course of treatment, but early-505 
stage interventions (when suboptimal dosing implementation is first detected) may prevent 506 
later discontinuation. For such interventions to be accurately targeted to the patients most in 507 
need, individual-level adherence data is required on a large scale. Shorter TB treatment 508 
regimens may reduce the impact of worsening adherence over the treatment course. 509 
  510 
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FIGURE LEGENDS 646 
Figure 1. Lasagna plot of adherence 647 
Each patient of the 780 participants in the control arm of the original trial is a row in the 648 
graph; white indicates a dose that has not been taken. Adherence calculated as a 649 
percentage of the 90 doses taken over the 180-day period and then grouped into 20% 650 
adherence intervals. Rows are colored by adherence group. Numbers in brackets indicate 651 
the number of individuals within each 20% adherence interval. 652 
 653 
  654 
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Figure 2. Relative contribution of discontinuation and suboptimal dosing 655 
implementation to non-adherence over time 656 
Non-adherence due to discontinuation (ceasing treatment and not re-commencing; dark 657 
grey) versus suboptimal dosing implementation (sporadic missed doses; light grey) over time 658 
in a) the 780 control arm patients from the original trial, b) the 659 patients would displayed 659 
≥80% adherence during the initiation phase, c) the 121 patients who displayed <80% 660 
adherence in the initiation phase. Discontinuation is ceasing treatment at any stage, 661 
including only for the 90th dose. If, after the 90th dose, another was taken before the end of 662 
the trial, the patient is not recorded as having discontinued. Discontinuation is not the same 663 
as programmatically defined loss to follow-up/default. Graph style adapted from the work of 664 
Blaschke et al.[28]  665 
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Figure 3. Gaps in adherence 668 
Gaps during the 90-dose medication period among the 748 participants who displayed 669 
suboptimal dosing implementation. Number of gaps per participant of any length plotted 670 
against a) the median gap length per participant, b) the maximum gap length per participant. 671 
  672 
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Table 1. Baseline characteristics. Unadjusted analyses of factors associated with non-adherence due to suboptimal dosing 673 
implementation or discontinuation 674 
  
  
Exposure variables 
Overall Analysis of suboptimal dosing implementation Analysis of discontinuation 
Participants Col. % Doses Col. % Doses missed 
Row 
% 
Unadjusted OR 
(95% CI) 
Person 
time 
(doses) 
Participants 
who 
discontinued 
Unadjusted HR 
(95% CI) 
Overall 780 100.0 62893 100.0 9487 15.1 - 62396 235 - 
Sex              
 Female 245 31.4 19804 31.5 2683 13.5 baseline 19649 161 baseline 
 Male 535 68.6 43089 68.5 6804 15.8 1.20 (0.99-1.45) 42747 74 1.00 (0.76-1.32) 
Age categorized (years)                
 <30 230 29.5 18305 29.1 2837 15.5 baseline 18157 69 baseline 
 30-39 128 16.4 10099 16.1 1315 13.0 1.01 (0.95-1.08) 10021 44 0.95 (0.87-1.04) 
 40-49 167 21.4 13518 21.5 2077 15.4   13422 56  
 50-59 136 17.4 11117 17.7 1712 15.4   11023 35  
 60+ 119 15.3 9854 15.7 1546 15.7   9773 31  
Occupation                
 Students 32 4.1 2529 4.0 428 16.9 1.01 (0.64-1.58) 2512 13 1.34 (0.76-2.37) 
 Worker 74 9.5 6102 9.7 722 11.8 0.61 (0.45-0.84) 6048 17 0.69 (0.42-1.15) 
 Migrant Worker 74 9.5 6167 9.8 815 13.2 0.76 (0.55-1.03) 6115 17 0.68 (0.41-1.13) 
 Farmer 384 49.2 30763 48.9 5347 17.4 baseline 30523 122 baseline 
 
Unemployed/ 
Houseworker 63 8.1 5207 8.3 624 12.0 0.60 (0.43-0.84) 5165 17 0.81 (0.49-1.35) 
 Other 153 19.6 12125 19.3 1551 12.8 0.68 (0.53-0.86) 12033 49 1.02 (0.73-1.42) 
Educational level                
 Illiterate 60 7.7 4595 7.3 858 18.7 1.38 (0.92-2.07) 4557 20 1.43 (0.79-2.59) 
 Lower middle school 494 63.3 39999 63.6 6254 15.6 1.03 (0.78-1.35) 39692 154 1.25 (0.82-1.93) 
 Upper middle school 130 16.7 10571 16.8 1216 11.5 0.73 (0.52-1.02) 10484 37 1.13 (0.68-1.89) 
 University or more 96 12.3 7728 12.3 1159 15.0 baseline 7663 24 baseline 
Total household income in last 
calendar year (RMB)                
 ≥20,000 446 57.2 36044 57.3 4994 13.9 baseline 35754 131 baseline 
 <20,000 334 42.8 26849 42.7 4493 16.7 1.31 (1.10-1.57) 26642 104 1.07 (0.83-1.38) 
Medical insurance                
 Rural co-op 500 64.1 40583 64.5 6604 16.3 1.23 (0.96-1.57) 40261 146 0.65 (0.48-0.89) 
 Urban workers 92 11.8 7843 12.5 946 12.1 0.86 (0.61-1.20) 7773 18 0.40 (0.24-0.69) 
 No insurance 132 16.9 9855 15.7 1350 13.7 baseline 9786 53 baseline 
 Other 56 7.2 4612 7.3 587 12.7 0.95 (0.64-1.41) 4576 18 0.71 (0.42-1.21) 
Marital status                
 1st marriage 551 70.6 45024 71.6 6707 14.9 baseline 44665 161 baseline 
 Unmarried 184 23.6 14421 22.9 2194 15.2 1.02 (0.82-1.26) 14305 57 1.11 (0.82-1.50) 
 Other 45 5.8 3448 5.5 586 17.0 1.15 (0.78-1.69) 3426 17 1.43 (0.87-2.35) 
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Table 1. continued 675 
  
  
Exposure variables 
Overall Analysis of suboptimal dosing implementation Analysis of discontinuation 
Participants Col. % Doses Col. % Doses missed  
Row 
% 
Unadjusted OR 
(95% CI) 
Person 
time 
(doses) 
Participants 
who 
discontinued 
Unadjusted HR 
(95% CI) 
County               
 Baiquan 100 12.8 7629 12.1 1926 25.2 baseline 7581 46 baseline 
 Yilan 103 13.2 8683 13.8 1113 12.8 0.40 (0.29-0.56) 8605 15 0.26 (0.15-0.47) 
 Rugao 78 10.0 6366 10.1 844 13.3 0.39 (0.27-0.56) 6310 21 0.52 (0.31-0.87) 
 Jianhu 80 10.3 6938 11.0 1270 18.3 0.60 (0.42-0.86) 6878 13 0.29 (0.16-0.54) 
 Miluo 85 10.9 6961 11.1 1131 16.2 0.55 (0.39-0.78) 6905 24 0.55 (0.34-0.90) 
 Yueyanglou 81 10.4 5893 9.4 718 12.2 0.35 (0.24-0.50) 5856 42 1.21 (0.79-1.83) 
 Fengjie 70 9.0 5115 8.1 684 13.4 0.39 (0.27-0.56) 5088 40 1.34 (0.88-2.04) 
 Shapingba 79 10.1 6311 10.0 915 14.5 0.49 (0.34-0.70) 6258 18 0.45 (0.26-0.78) 
 Jiangbei 104 13.3 8997 14.3 886 9.8 0.29 (0.21-0.40) 8915 16 0.27 (0.16-0.49) 
Rural/urban                
 Rural 516 66.2 41692 66.3 6968 16.7 baseline 41367 159 baseline 
 Urban 264 33.8 21201 33.7 2519 11.9 0.67 (0.55-0.81) 21029 76 0.94 (0.71-1.23) 
Residence                
 
Living in place of 
household registration 658 84.4 53187 84.6 8191 15.4 baseline 52768 198 baseline 
 
Not living in place of 
household registration 122 15.6 9706 15.4 1296 13.4 0.80 (0.62-1.03) 9628 37 1.03 (0.72-1.46) 
Distance from home to local TB 
clinic (km)                
 <10 188 24.1 15984 25.4 2255 14.1 baseline 15847 37 baseline 
 10-19 191 24.5 15185 24.1 2199 14.5 1.05 (0.99-1.12) 15065 63 1.14 (1.04-1.24) 
 20-29 118 15.1 9596 15.3 1451 15.1   9524 40 - 
 30-39 149 19.1 11802 18.8 1782 15.1   11714 49 - 
 >=40 134 17.2 10326 16.4 1800 17.4   10246 46 - 
Day           p<0.001     
 Sunday - -  9009 14.3 1516 16.8 baseline - - - 
 Monday  - -  8997 14.3 1301 14.5 0.81 (0.74-0.89) - - - 
 Tuesday  - -  8939 14.2 1344 15.0 0.84 (0.77-0.92) - - - 
 Wednesday  - -  9004 14.3 1315 14.6 0.83 (0.76-0.91) - - - 
 Thursday  - -  8895 14.1 1426 16.0 0.93 (0.85-1.01) - - - 
 Friday  - -  9275 14.7 1251 13.5 0.74 (0.68-0.81) - - - 
 Saturday  - -  8774 14.0 1334 15.2 0.87 (0.80-0.95) - - - 
  676 
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Table 1. continued 677 
  
  
Exposure variables 
Overall Analysis of suboptimal dosing implementation Analysis of discontinuation 
Participants Col. % Doses Col. % Doses missed 
Row 
% 
Unadjusted OR 
(95% CI) 
Person 
time 
(doses) 
Participants 
who 
discontinued 
Unadjusted HR 
(95% CI) 
Weekend           p<0.001    
 Weekday -  -  45110 71.7 6637 14.7 baseline - - - 
 Weekend -  -  17783 28.3 2850 16.0 1.13 (1.07-1.19) - - - 
Month          p<0.001     
 1 - -  11687 18.6 789 6.8 baseline - - - 
 2  - -  11298 18.0 1383 12.2 2.92 (2.60-3.28) - - - 
 3  - -  10800 17.2 1857 17.2 5.35 (4.66-6.13) - - - 
 4  - -  10314 16.4 1843 17.9 5.78 (4.91-6.81) - - - 
 5  - -  9770 15.5 1839 18.8 6.31 (5.21-7.65) - - - 
 6  - -  9024 14.3 1776 19.7 6.26 (5.01-7.83) - - - 
National holidays          p<0.001     
 No  - -  58018 92.2 8487 14.6 baseline - - - 
 Yes  - -  4875 7.8 1000 20.5 1.62 (1.49-1.75) - - - 
Phase          p<0.001     
 Initiation  - -  22985 36.5 2172 9.4 baseline - - - 
 Continuation  - -  39908 63.5 7315 18.3 3.09 (2.70-3.54) - - - 
Initiation phase adherence*              p=0.003 
 ≥90% - -  - - - - -  47419 137 baseline 
 80-90% - -   - - - - -  7373 22 1.05 (0.67-1.64) 
 <80% - -   - - - - -  6819 36 1.98 (1.37-2.86) 
Month 1 adherence**              p=0.003 
 ≥90%  - -   - - - - -  51106 171 baseline 
 80-90%  - -   - - - - -  7471 34 1.39 (0.96-2.00) 
  <80%  - -   - -  - - -  3757 25 2.10 (1.38-3.19) 
Leftmost data columns: baseline characteristics of the 780 individuals from the control arm of the original trial. Middle data columns: unadjusted mixed-effects 678 
logistic regression for the 780 individuals included in the analysis of suboptimal dosing implementation. Each model adjusted for clustering by patient. Age 679 
and distance to TB clinic modelled as linear variables. Random effect modelled on the initiation-continuation phase and month variables within the relevant 680 
unadjusted model. Rightmost data columns: unadjusted Cox regression for the 780 individuals included in the analysis of discontinuation. *740 individuals in 681 
the initiation phase adherence model and **775 in the month 1 adherence model; these exposure variables document non-adherence due to suboptimal 682 
dosing implementation only. Age and distance to TB clinic modelled as linear variables. All columns: no data were missing for any of the variables. - - not 683 
applicable, CI- confidence interval, Col- column, HR- hazard ratio, km- kilometres, OR-odds ratio, RMB- Renminbi, TB- tuberculosis 684 
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Table 2. Adjusted odds ratios for the association between suboptimal dosing 685 
implementation and a) treatment month, stratified by national holidays or b) national 686 
holidays, stratified by treatment month 687 
    National holidays 
    No Yes 
Treatment month, stratified by national holidays 
Treatment month 1 baseline baseline 
2 2.87 (2.55-3.23) 3.32 (2.15-5.15) 
3 5.23 (4.55-6.01) 5.82 (3.81-8.90) 
4 5.58 (4.72-6.58) 7.34 (4.76-11.31) 
5 6.23 (5.13-7.57) 6.45 (4.11-10.12) 
6 5.90 (4.71-7.40) 10.01 (6.27-15.98) 
National holidays, stratified by treatment month 
Treatment month 1 baseline 1.25 (0.85-1.84) 
2 baseline 1.45 (1.15-1.82) 
3 baseline 1.39 (1.16-1.67) 
4 baseline 1.64 (1.36-1.98) 
5 baseline 1.29 (1.06-1.58) 
6 baseline 2.12 (1.71-2.62) 
Adjusted regression of the association between non-adherence due to suboptimal dosing 688 
implementation and treatment month, stratified by national holidays (top rows) or national holidays, 689 
stratified by treatment month (bottom rows); Model 2. 62,893 doses from 780 individuals from the 690 
control arm of the original trial included. The stratum-specific ORs are adjusted for weekends, age, 691 
sex and rural-urban. Random effect modelled on the month variable. Age modelled as a linear 692 
variable. Results per cell presented as OR (95% CI). CI- confidence interval, OR- odds ratio 693 
  694 
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Table 3. Adjusted Cox regression models of the association between early suboptimal 695 
dosing implementation and discontinuation 696 
Temporal factor Hazard ratio (95% CI) 
MODEL 3   
Initiation phase adherence  p=0.004 
 ≥90% baseline 
 80-<90% 1.04 (0.66-1.63) 
  <80% 1.97 (1.36-2.85) 
MODEL 4   
Month 1 adherence p=0.004 
 ≥90% baseline 
 80-<90% 1.37 (0.95-1.99) 
 <80% 2.06 (1.35-3.15) 
Model 3 examines the association between non-adherence in the initiation phase due to suboptimal 697 
dosing implementation and discontinuation, adjusting for age, sex and rural-urban. It excludes 698 
individuals who discontinued in the initiation phase, leaving 740. Model 4 examines the association 699 
between non-adherence in the month 1 due to suboptimal dosing implementation and discontinuation, 700 
adjusting for age, sex and rural-urban. It excludes individuals who discontinued during month 1, 701 
leaving 775. Age modelled as a linear variable. CI- confidence interval 702 
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Additional Methods 712 
Parent study and study population for analysis: additional details 713 
Between 1st June 2011 and 7th March 2012, in the Heilongjiang, Jiangsu, Hunan, and 714 
Chongqing provinces of the People’s Republic of China, 4,173 eligible pulmonary TB 715 
patients placed on the standard six-month anti-tuberculosis regimen were consented to be 716 
enrolled in a pragmatic cluster randomized trial of electronic reminders (short message 717 
service [SMS] and audio reminders from a medication monitor box) to improve treatment 718 
adherence.(29) The thirty-six clusters were rural counties or urban districts within these 719 
provinces. In all arms of the study, each month a patient’s medication was placed in their 720 
medication monitor box by local health service staff. The box captured every date and time 721 
on which it was opened. These data were downloaded at the monthly clinic visits, at which 722 
new medication was dispensed. 723 
 724 
Within the control arm of the trial, participants were managed according to the standard of 725 
care of the National TB Control Program (NTP). They received no electronic reminders to 726 
take their medications; their treatment was either self-administered, or supervised by family 727 
members or health care workers. Further restrictions to be included within the cohort 728 
analyzed in this study were: having no power outage problems with the medication monitor 729 
(resulting in box opening not being recorded), no hospital inpatient stay greater than three 730 
days, no pausing/stoppage of treatment due to side effects, and being enrolled into the trial 731 
on the same day as TB registration such that treatment had not already started and thus all 732 
doses could be captured.     733 
 734 
Measuring and defining adherence to treatment: interpreting data from the medication 735 
monitor 736 
Data from the medication monitor box were interpreted as follows. If the box was opened at 737 
least once within each two-day dosing window this was recorded as adherence, together 738 
with the date. If the box was not opened within this period no adherence data were recorded 739 
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by the monitor. To document non-adherence at any point, we inferred the dates of missed 740 
doses and thus non-adherence when the monitor did not record being opened. Data from 741 
the first 180 days were used in the analysis; data on doses taken after this period were not 742 
used. 743 
 744 
Temporal exposures and confounding: additional information about categorization 745 
The following temporal measures were calculated from the medication monitor data: 1) the 746 
day of the week on which each expected dose of medication fell, 2) the treatment month of 747 
the dose (expected doses 1-15 fell in month 1, etc.), 3) whether the expected dose fell on a 748 
Chinese national holiday, and finally 4) the first 30 expected doses were assigned to the 749 
initiation phase of treatment and the last 60 doses to the continuation phase. The latter 750 
division is the norm for TB treatment; in the initiation phase four drugs are used for two 751 
months, in the continuation phase two drugs are used for four months. The Chinese national 752 
holidays considered were New Year (January), Chinese New Year (January), Tomb 753 
Sweeping Day (April), Labor Day (April/May), The Dragon Boat festival (June), mid-autumn 754 
festival (September), and National Day (October).  755 
 756 
Levels of suboptimal dosing implementation in the initiation phase and month 1 were also 757 
calculated and categorized. 758 
 759 
Associations between temporal factors and suboptimal dosing implementation: 760 
detailed methodology used 761 
Adherence data were included for each patient up until the last dose taken before a 762 
permanent stoppage of treatment (discontinuation) or the 180-day end point of the regimen, 763 
whichever was sooner. Doses after the 180-day (90 dose) point were considered when 764 
assessing discontinuation, however (see Methods: Measuring and defining adherence to 765 
treatment). 766 
 767 
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Our analyses focused on the temporal factors of weekends, national holidays and, 768 
separately, either the initiation-continuation phase transition (Model 1) or treatment months 769 
(Model 2). Having drawn a directed acyclical graph (DAG), the following were deemed a 770 
priori confounders: age, sex and rural-urban. Assessing the effect of treatment months in 771 
place of the initiation-continuation phase transition was decided upon ad hoc, after 772 
examining our line graphs. 773 
 774 
When building our main adjusted model (Model 1) the following factors were additionally 775 
considered from the DAG. On the basis of biological plausibility age, treatment month and 776 
distance to tuberculosis (TB) clinic were selected a priori for an assessment of goodness of 777 
fit as linear or categorical variables. Effect estimates across strata were compared and 778 
likelihood ratio tests (LRTs) undertaken. Additionally, interactions between national 779 
holidays/weekends and the initiation-continuation phase transition or treatment month were 780 
tested for using LRTs. The impact of adding a random effect for treatment month and 781 
initiation-continuation phase, such that their effect varied between individuals, was also 782 
assessed using LRTs. 783 
 784 
Model 1 was adapted by adjusting for different sets of potential confounders in place of rural-785 
urban in addition to the a priori confounders. These potential confounders could not all be 786 
simultaneously assessed due to collinearity. The confounder sets were: distance from home 787 
to local TB clinic (Model 1A), medical insurance (Model 1B), occupation (Model 1C), rural-788 
urban and education level (Model 1D), rural-urban and total household income in the last 789 
year (Model 1E). 790 
 791 
A sensitivity analysis was conducted to examine the impact of potential clustering by 792 
county/district, by including this variable as a fixed effect in place of rural-urban (Model 1F). 793 
It could not be included as a random effect, due to the small number of counties/districts. 794 
 795 
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Associations between early suboptimal dosing implementation and time to 796 
discontinuation: detailed methodology used 797 
Non-adherence due to suboptimal dosing implementation was categorized into three levels: 798 
<80%, 80-89% and ≥90%. The same a priori confounders and rural-urban variable were 799 
adjusted for as previously, on the basis of a DAG. The validity of the proportional hazards 800 
assumption was assessed using a likelihood ratio test (LRT) for an interaction between time 801 
and the main exposure of interest. 802 
 803 
A sensitivity analysis was also conducted for Models 3 and 4 using a fixed effect for 804 
county/district in place of rural-urban status (Models 3F and 4F). An additional analysis 805 
excluded individuals who discontinued during the last three doses (approximately a week), in 806 
order to focus on earlier time points of discontinuation (Models 3G and 4G). 807 
  808 
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Table E1. Comparison of baseline characteristics between individuals included in and 809 
excluded from the analysis cohort 810 
p-values from Χ2 tests. 811 
Exposure variables 
Analysis dataset 
Included Col. % Excluded Col. % p-value 
Overall   780 70.7 324 29.3  
Sex         p=0.09 
 Male 535 68.6 239 73.8  
 Female 245 31.4 85 26.2   
Age categorised (years)       p=0.73 
 <30 230 29.5 103 31.8  
 30-39 128 16.4 49 15.1   
 40-59 303 38.8 129 39.8   
 60+ 119 15.3 43 13.3   
Occupation       p=0.28 
 Students 32 4.1 22 6.8  
 Worker 74 9.5 27 8.3   
 Migrant Worker 74 9.5 24 7.4   
 Farmer 384 49.2 156 48.1   
 Unemployed/Houseworker 63 8.1 22 6.8   
 Other 153 19.6 73 22.5   
Educational level       p=0.61 
 Illiterate 60 7.7 21 6.5  
 Lower middle school 494 63.3 199 61.4   
 Upper middle school 130 16.7 64 19.8   
 University or more 96 12.3 40 12.3   
Total household income in last calendar year 
(RMB)       p=0.92 
 ≥20,000 320 41.0 134 41.4  
 <20,000 460 59.0 190 58.6   
Medical insurance       p=0.56 
 Rural co-op 500 64.1 210 64.8  
 Urban workers 92 11.8 42 13.0   
 No insurance 132 16.9 56 17.3   
 Other 56 7.2 16 4.9   
Marital status       p=0.41 
 1st marriage 551 70.6 219 67.6  
 Unmarried 184 23.6 80 24.7   
 Other 45 5.8 25 7.7   
County         p<0.001 
 Baiquan 100 12.8 25 7.7  
 Yilan 103 13.2 20 6.2   
 Rugao 78 10.0 40 12.3   
 Jianhu 80 10.3 39 12.0   
 Miluo 85 10.9 33 10.2   
 Yueyanglou 81 10.4 38 11.7   
 Fengjie 70 9.0 60 18.5   
 Shapingba 79 10.1 52 16.0   
 Jiangbei 104 13.3 17 5.2   
Rural/urban       p=0.79 
 Rural 516 66.2 217 67.0  
 Urban 264 33.8 107 33.0   
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Table E1. continued 813 
Exposure variables 
Analysis dataset 
Included Col. % Excluded Col. % p-value 
Residence     p=0.97 
 
Living in place of household 
registration 658 84.4 273 84.3  
 
Not living in place of household 
registration 122 15.6 51 15.7   
Distance from home to local TB clinic (km)       p=0.003 
 <10 188 24.1 69 21.3  
 10-29 309 39.6 117 36.1   
 30-39 149 19.1 51 15.7   
 >=40 134 17.2 87 26.9   
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Table E2. Adjusted logistic regression of the association between temporal factors 815 
and suboptimal dosing implementation, adjusting for different confounder sets 816 
Adjusted models of the association between the temporal factors weekend, national holidays, and 817 
treatment phase and the outcome of non-adherence due to suboptimal dosing implementation. All 818 
models derive from Model 1. Each adjusts for the other temporal factors listed in the relevant stratum 819 
of the table plus age, sex and: distance from home to local TB clinic rather than rural-urban (Model 820 
1A), medical insurance rather than rural-urban (Model 1B), occupation rather than rural-urban (Model 821 
1C), both rural-urban and education level (Model 1D), rural-urban and total household income in last 822 
calendar year (Model 1E), county/district rather than rural-urban (Model 1F). 62,893 doses from 780 823 
individuals in the control arm of the original trial included. Random effect modelled on the initiation-824 
continuation phase variable. Age and distance to TB included as linear variables, where relevant. CI- 825 
confidence interval, OR- odds ratio, TB- tuberculosis. 826 
Temporal factor OR (95% CI) 
MODEL 1A  
Weekend    p<0.001 
 Weekday baseline 
 Weekend 1.14 (1.08-1.20) 
National holidays   p<0.001 
 No baseline 
 Yes 1.52 (1.39-1.65) 
Phase   p<0.001 
 Initiation baseline 
  Continuation 3.07 (2.68-3.51) 
MODEL 1B  
Weekend    p<0.001 
 Weekday baseline 
 Weekend 1.14 (1.08-1.20) 
National holidays    p<0.001 
 No baseline 
 Yes 1.52 (1.39-1.65) 
Phase    p<0.001 
 Initiation baseline 
  Continuation 3.07 (2.68-3.51) 
MODEL 1C  
Weekend    p<0.001 
 Weekday baseline 
 Weekend 1.14 (1.08-1.20) 
National holidays    p<0.001 
 No baseline 
 Yes 1.52 (1.39-1.65) 
Phase    p<0.001 
 Initiation baseline 
  Continuation 3.08 (2.69-3.53) 
MODEL 1D  
Weekend    p<0.001 
 Weekday baseline 
 Weekend 1.14 (1.08-1.20) 
National holidays    p<0.001 
 No baseline 
 Yes 1.52 (1.39-1.65) 
Phase    p<0.001 
 Initiation baseline 
  Continuation 3.06 (2.67-3.50) 
MODEL 1E  
Weekend    p<0.001 
 Weekday baseline 
 Weekend 1.14 (1.08-1.20) 
National holidays    p<0.001 
 No baseline 
 Yes 1.52 (1.39-1.65) 
Phase    p<0.001 
 Initiation baseline 
  Continuation 3.07 (2.69-3.52) 
 827 
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Table E2. continued 829 
 830 
Temporal factor OR (95% CI) 
MODEL 1F  
Weekend    p<0.001 
 Weekday baseline 
 Weekend 1.14 (1.08-1.20) 
National holidays    p<0.001 
 No baseline 
 Yes 1.52 (1.39-1.65) 
Phase    p<0.001 
 Initiation baseline 
  Continuation 3.14 (2.74-3.60) 
 831 
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Table E3. Adjusted odds ratios for the association between suboptimal dosing 833 
implementation and the initiation-continuation phase transition, stratified by county 834 
    Phase 
    Initiation Continuation 
County Baiquan baseline 5.12 (3.69-7.11) 
Yilan baseline 2.64 (1.88-3.71) 
Rugao baseline 2.12 (1.44-3.13) 
Jianhu baseline 2.63 (1.83-3.78) 
Miluo baseline 3.31 (2.28-4.78) 
Yueyanglou baseline 2.48 (1.65-3.73) 
Fengjie baseline 4.18 (2.71-6.44) 
Shapingba baseline 4.05 (2.75-5.98) 
Jiangbei baseline 2.44 (1.73-3.45) 
Adjusted regression of the association between non-adherence due to suboptimal dosing 835 
implementation and the initiation-continuation phase transition (Model 1), stratified by county (Model 836 
1G). 62,893 doses from 780 individuals from the control arm of the original trial included. The stratum-837 
specific ORs are adjusted for weekends, holidays, age, sex and county. Random effect modelled on 838 
the initiation-continuation phase variable. Age modelled as a linear variable. Results per cell 839 
presented as OR (95% CI). CI- confidence interval, OR- odds ratio 840 
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Table E4. Adjusted odds ratios for the association between suboptimal dosing 842 
implementation and holidays, stratified by county 843 
    Holiday 
    No Yes 
County Baiquan baseline 0.94 (0.75-1.18) 
Yilan baseline 1.49 (1.18-1.88) 
Rugao baseline 1.43 (1.08-1.89) 
Jianhu baseline 1.39 (1.10-1.77) 
Miluo baseline 1.77 (1.37-2.28) 
Yueyanglou baseline 1.57 (1.17-2.11) 
Fengjie baseline 1.41 (1.02-1.94) 
Shapingba baseline 1.75 (1.35-2.27) 
Jiangbei baseline 2.37 (1.89-2.96) 
Adjusted regression of the association between non-adherence due to suboptimal dosing 844 
implementation and holidays (Model 1), stratified by county (Model 1H). 62,893 doses from 780 845 
individuals from the control arm of the original trial included. The stratum-specific ORs are adjusted 846 
for weekends, initiation-continuation phase transition, age, sex and county. Random effect modelled 847 
on the initiation-continuation phase variable. Age modelled as a linear variable. Results per cell 848 
presented as OR (95% CI). CI- confidence interval, OR- odds ratio 849 
  850 
46 
 
Table E5. Adjusted Cox regression models of the association between early 851 
suboptimal dosing implementation and discontinuation- sensitivity analysis 852 
Sensitivity analysis of the association between suboptimal dosing implementation in the initiation 853 
phase or month 1, and discontinuation. Model 3F examines the association between suboptimal 854 
dosing implementation in the initiation phase and discontinuation, adjusting for age, sex and 855 
county/district (as opposed to rural-urban in Model 3). It excludes individuals who discontinued in the 856 
initiation phase, leaving 740. Model 3G examines the association between suboptimal dosing 857 
implementation in the initiation phase and discontinuation whilst excluding individuals who 858 
discontinued after dose 86 (688 people in the model) and adjusts for the same confounders as Model 859 
3. Model 4F examines the association between suboptimal dosing implementation in month 1 and 860 
discontinuation, adjusting for age, sex and county/district (as opposed to rural-urban in Model 4). It 861 
excludes individuals who discontinued during month 1, leaving 775. Model 4G examines the 862 
association between suboptimal dosing implementation in month 1 and discontinuation whilst 863 
excluding individuals who discontinued after dose 86 (723 people in the model) and adjusts for the 864 
same confounders as Model 4. Age modelled as a linear variable in all models. CI- confidence 865 
interval. 866 
Temporal factor Hazard ratio (95% CI) 
MODEL 3F   
Initiation phase adherence  p=0.001 
 ≥90% baseline 
 80-<90% 1.17 (0.74-1.84) 
  <80% 2.14 (1.46-3.14) 
MODEL 3G   
Initiation phase adherence  p=0.001 
 ≥90% baseline 
 80-<90% 1.28 (0.78-2.09) 
  <80% 2.40 (1.59-3.62) 
MODEL 4F  
Month 1 adherence p=0.002 
 ≥90% baseline 
 80-<90% 1.53 (1.05-2.22) 
  <80% 2.06 (1.33-3.16) 
MODEL 4G   
Month 1 adherence p=0.001 
 ≥90% baseline 
 80-<90% 1.51 (1.00-2.28) 
  <80% 2.39 (1.52-3.78) 
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FIGURE LEGENDS 1005 
Figure E1. Flow chart of participants 1006 
Flow chart documenting participation from the original trial to this study. Side effects could 1007 
lead to temporary or permanent medication stoppage; in either instance, adherence data 1008 
were no longer collected. 1009 
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